Phase 1 Deliverable Only — Discovery & Ethnopharmacological Scouting

SCF API DEVELOPMENT PIPELINE INITIATION

Phase 1 Deliverable Only — Discovery & Ethnopharmacological Scouting

Candidate API: Glymorisulfonin™

Program: AETERNAVIR™ Immunotherapeutic Payload Development

Phase Objective

Per the SCF Ethnobioprospecting Workflow, Phase 1 is used to retrieve and prioritize traditional bioactive sources for pharmacological development through: ethnobotanical data collection, screening of documented traditional therapeutic roles, and mapping to modern disease states or molecular pathways. The AETERNAVIR dossier assigns Glymorisulfonin™ as the immunotherapeutic payload with locked SCF roles F5/F8 and a non-negotiable function of immune-lymphatic reprogramming, with an updated description including reservoir clearance intent.

1. Phase 1 Scope Statement

Because the provided documents define Glymorisulfonin™ functionally but do not provide a confirmed natural-source identity or established chemical provenance, this Phase 1 deliverable initiates the SCF pipeline by establishing a provisional ethnobioprospecting origin hypothesis, a source-prioritization matrix, and a lead-source nomination for downstream extraction and mechanistic profiling. This is consistent with the SCF API Discovery Profile requirement to derive a geographically and culturally aligned ethnobioprospecting source before Phase 2 extraction and SCF analysis.

2. Phase 1 Output: Ethnopharmacological Scouting Report

2.1 Therapeutic Design Intent for Glymorisulfonin™

Interpretive note: The required biological behavior is not generic “immune stimulation.” It is a more selective profile: immune recalibration, lymphatic tissue relevance, inflammation control, and compatibility with chronic antiviral co-administration.

2.2 Ethnomedical Search Domain Selection

The SCF workflow explicitly allows ethnopharmacological scouting across TCM, Ayurveda, Amazonian, and other traditional medicine systems. The internal SCF biodiversity files provide the densest source material for Amazon Basin candidates, including potency-ranked species, therapeutic-domain annotations, and multi-omic pathway mapping for immune regulation and infectious-disease relevance.

2.3 Phase 1 Disease-to-Pathway Mapping

Using the AETERNAVIR program definition and the SCF extraction protocol requirement to map traditional use to disease-relevant pathways and target tissues, the following Phase 1 target map is adopted for Glymorisulfonin™: immune checkpoint dysregulation, macrophage polarization, cytokine desynchronization, lymphoid/GALT tissue persistence, NF-κB/JAK-STAT/TLR4 immune signaling, and chronic inflammatory drift relevant to HIV reservoir maintenance.

3. Longlist of Ethnobioprospecting Source Candidates

3.1 Phase 1 Candidate Set

From the Amazon Basin SCF databases, the following candidates are the most relevant initial leads for an immune-lymphatic immunotherapeutic payload:

These entries are directly supported by the Amazon SCF medicinal-species and pharmacological super-database materials.

4. Source Prioritization Logic

4.1 SCF Selection Criteria Applied

The SCF extraction and API-discovery documents require prioritization based on historical relevance, empirical evidence, pathway alignment, source authentication feasibility, and later compatibility with SCF role assignment and synergy architecture.

4.2 Weighted Prioritization Matrix

Phase 1 result: Uncaria tomentosa is nominated as the primary ethnobioprospecting lead source for Glymorisulfonin™. Petiveria alliacea is retained as the secondary sulfur-scaffold comparator source for Phase 2 extraction.

5. Lead-Source Nomination

5.1 Primary Lead

Lead Ethnobioprospecting Source: Uncaria tomentosa

Rationale: The internal SCF database ranks Uncaria tomentosa among top-tier Amazonian bioactives, identifies oxindole alkaloids as key actives, and classifies it as immunomodulatory with a QPS of 820, making it one of the strongest available candidates for a payload intended to reprogram immune-lymphatic behavior within a chronic viral setting.

5.2 Secondary Comparator

Comparator Source: Petiveria alliacea

Rationale: The same database identifies sulfur compounds and resistance-prevention logic in Petiveria alliacea, making it especially valuable as a comparator for the “sulfonin” design logic and as a possible source of sulfur-bearing semi-synthetic scaffold elements for later analog engineering.

6. Provisional Biomedical Translation Hypothesis

6.1 Working Hypothesis

Glymorisulfonin™ is provisionally defined as an SCF-engineered immuno-lymphatic API candidate derived from an Amazonian immunomodulatory ethnobotanical lead, with primary discovery emphasis on Uncaria tomentosa and sulfur-scaffold comparator support from Petiveria alliacea.

6.2 Translational Mechanistic Hypothesis

The therapeutic concept is that a lead scaffold or enriched fraction from Uncaria tomentosa, potentially later refined by sulfur-bearing analog optimization informed by Petiveria alliacea, may produce a more clinically useful immunotherapeutic profile characterized by:

• macrophage and cytokine recalibration rather than indiscriminate activation,
• reduced inflammatory drift linked to reservoir persistence,
• improved lymphoid/GALT tissue immune fitness,
• support of long-term antiviral control when paired with integrase blockade.

This Phase 1 framing is consistent with the SCF requirement to map traditional uses to modern disease-relevant pathways before extraction and to assign later SCF therapeutic roles after mechanistic profiling.

7. Phase 1 Deliverables Locked for Advancement to Phase 2

Advancement Decision

Go / No-Go Outcome: GO to Phase 2

Phase 2 Entry Materials:

1. Uncaria tomentosa authenticated source-specimen plan
2. Petiveria alliacea comparator extraction plan
3. Pre-extraction target panel focused on immune/lymphatic and reservoir-relevant signaling
4. Fractionation strategy for alkaloid-rich and sulfur-rich discovery lanes

8. Regulatory-Framed Phase 1 Conclusion

Phase 1 has been successfully initiated under the SCF Ethnobioprospecting Workflow and aligned to the AETERNAVIR immunotherapeutic payload mandate. The current evidence base in the provided documents is sufficient to justify source selection and pathway mapping, but not yet sufficient to claim a definitive chemical identity for Glymorisulfonin™. That identity must be established in Phase 2 Bioactive Compound Extraction & SCF Analysis through authenticated sourcing, extraction, MoA/MeA profiling, and SCF role confirmation.

Reference files:

MASTER REGISTRY INDEX

SCF-HIV-AET-GLY-PIPE-0001

SCF-ETHBIO-WF-0001

SCF-API-DP-0001

SCF-SEF-MD-0001

SCF-ABMD-DB-0001

SCF-ABMD-SDB-0002